Rubicon, the NZX-listed forestry biotech company that controls Tenon has teamed with US and New Zealand investors to agree to buy the wood processing company's remaining asset, the Clearwood manufacturing business, for US$55 million (NZ$76.6m), a deal that would actually free up cash and reduce Rubicon's exposure.
The deal needs sign-off from Tenon shareholders before it can be settled on the target date of April 28. Tenon is tied to the transaction by a US$1.65m termination fee if it halts the sale plus costs for the bidding group of up to US$500,000.
The offer amounts to $2.12 a share net of costs, or $2.39 before costs, within the sale and liquidation range in an assessment by Grant Samuel, they said. It also exceeds the top end of value range if Tenon was to continue with the business.
"Deutsche-Craigs ran an exhaustive sales process for Tenon, generating expressions of interest from eight parties, domestic and international," but the Rubicon-led offer was deemed to be the best by the two independent directors. Tenon's three directors linked to Rubicon weren't involved in evaluating the offer.
"Given an extensive investment bank-led process has been run, Tenon's independent directors have accepted the consortium's offer and signed the sale and purchase agreement as being in the best interests of Tenon shareholders," the company said.